Niox Group plc develops and commercializes medical devices for the measurement of fractional exhaled nitric oxide (FeNO), which is used in the diagnosis and management of asthma and other respiratory conditions. The company operates a distributor-led business model, providing support and training to its distributor network across over 50 markets globally, including North America, Europe, Asia, and parts of Africa and the Middle East. Niox generates revenue primarily through clinical sales to healthcare providers and research sales to pharmaceutical companies and contract research organizations. Its product offerings include the NIOX VERO® and the next-generation NIOX PRO® devices.
Niox Group plc develops and commercializes medical devices for the measurement of fractional exhaled nitric oxide (FeNO), which is used in the diagnosis and management of asthma and other respiratory conditions. The company operates a distributor-led business model, providing support and training to its distributor network across over 50 markets globally, including North America, Europe, Asia, and parts of Africa and the Middle East. Niox generates revenue primarily through clinical sales to healthcare providers and research sales to pharmaceutical companies and contract research organizations. Its product offerings include the NIOX VERO® and the next-generation NIOX PRO® devices.
